How would you approach patients with EGFR mutation positive (exon 19) NSCLC who rapidly progress on front line EGFR inhibition with first generation TKI at first imaging?   

Can T790M mutation develop within this early time frame, or are these perhaps patients who may benefit from switch to chemotherapy?



Answer from: Medical Oncologist at Academic Institution